ClinicalTrials.gg
CompletedNCT04442295Updated May 18, 2025

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

A Phase 1/2 interventional study of STK-001 - Single Ascending Doses and STK-001 - Multiple Ascending Doses in Dravet Syndrome, sponsored by Stoke Therapeutics, Inc. Completed at 18 sites in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Stoke Therapeutics, Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.

Enrollment
17th of 43
62 · median 36
Started
2020
with 3 others
Phase 1/2
6 of 61
3 open now
Registered
32nd of 61
by date
Lead sponsor
3 of 61
Stoke Therapeutics, Inc

Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 17th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 1/2, and was the 32nd registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Epilepsies, Myoclonic with a site in United States, or all of them as a file.
02

Study summary

Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Read the detailed description

STK-001 is an investigational new medicine for the treatment of Dravet syndrome. STK-001 is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).

STK-001 is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.

03

Conditions studied

  • Dravet Syndrome

Browse trials for

Keywords

  • Pediatric epilepsy
  • Epileptic Encephalopathies
  • Refractory Myoclonic Epilepsy
  • Severe Myoclonic Epilepsy in Infancy
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Dravet Syndrome (DS) with onset of recurrent focal motor or hemiconvulsive or generalized tonic-clonic seizures prior to 12 months of age, which are often prolonged and triggered by hyperthermia.

    • No history of causal MRI lesion
    • No other known etiology
    • Normal development at seizure onset.
  • Documented pathogenic, likely pathogenic variant, or variant of uncertain significance in the SCN1A gene associated with DS.
  • Use of at least 2 prior treatments for epilepsy that either had lack of adequate seizure control (requiring an additional AED) or had to be discontinued due to an AE(s).
  • Currently taking at least one AED at a dose which has been stable for at least 4 weeks prior to Screening.
  • Stable epilepsy medications or interventions for epilepsy (including ketogenic diet or vagal nerve stimulator) for at least 4 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • Known pathogenic mutation in another gene that causes epilepsy
  • Currently treated with an AED acting primarily as a sodium channel blocker, as maintenance treatment, including: phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide.
  • unstable medical conditions other than epilepsy.
  • Clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to Screening or prior to dosing on Day 1, other than epilepsy.
  • History of brain or spinal cord disease (other than epilepsy or DS), or history of bacterial meningitis or brain malformation
  • Spinal deformity or other condition that may alter the free flow of cerebrospinal fluid (CSF) or has an implanted CSF drainage shunt.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, may influence the results of the study, or may affect the patient's ability to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Single Ascending Doses

    Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive single doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 5 additional patients.

    Drug: STK-001 - Single Ascending Doses

  • Experimental
    Multiple Ascending Doses

    Enrollment of patients in two age groups. A Sentinel group of 2 patients aged 13 to 18 years of age, inclusive, and an expanded group of 2 patients 2 to 12 years of age to receive multiple doses. There will be an option to dose up to 6 additional patients at each dose level and an option to expand the maximum tolerated dose level with 10 additional patients.

    Drug: STK-001 - Multiple Ascending Doses

Interventions

  • Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).

  • Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of single and multiple doses of STK-001 with respect to:

    1. Incidence of adverse events 2. incidence of abnormal vital signs 3. Abnormal physical examination findings 4. Abnormal 12-lead electrocardiogram (ECG) 5. Abnormal laboratory parameters

    Time frame: Screening (Day -28) until 6 months after single and multiple drug dosing

  2. Pharmacokinetic (PK) Parameters

    Analysis of plasma concentrations of STK-001

    Time frame: Day 1 (Dosing) until 6 months after single and multiple drug dosing

  3. Exposure of STK-001 in Cerebrospinal Fluid (CSF)

    Measurement of STK-001 concentrations

    Time frame: Day 1 (Dosing) until 6 months after single and multiple drug dosing

Secondary outcomes

  1. Measurement of seizure frequency

    Measured by paper diary

    Time frame: Screening (Day -28) until 6 months after single and multiple drug dosing

  2. Change in Caregiver Global Impression of Change Scale

    Change from baseline in overall clinical status as measured by the Clinical Global Impression of Change (CGIC). Values of scales: 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: Baseline (Day -1) until 6 months after single and multiple drug dosing

  3. Change in Clinician-assessed Global Impression of Change Scale

    Change from baseline in overall clinical status as measured by the Caregiver Global Impression of Change (CaGIC) Values of scales: 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: Baseline (Day -1) until 6 months after single and multiple drug dosing

  4. Measurement of Quality of Life

    Change in quality of life as measured by the EuroQoL-five dimensions, youth version (EQ-5D-Y) instrument. The scale is scored from 0-100. The reference to a high score indicates a better outcome of quality of life.

    Time frame: Baseline (Day -1) until 6 months after single and multiple drug dosing

07

Study locations

18 sites
  • UCSF Benioff Children's Hospital
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Hospitals and Clinics; Pediatric Specialty Clinic
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital - Pediatric Epilepsy Program
    Boston, Massachusetts 02114, United States
  • University of Michigan - Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • NYU Comprehensive Epilepsy Center
    New York, New York 10016, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38105, United States
  • Cook Children's Health Care System
    Fort Worth, Texas 76104, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84108, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Multicare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Nov 2023, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2020
First posted
Jun 22, 2020
StartActual
Jun 29, 2020
Primary completionActual
Nov 14, 2023
CompletionActual
Nov 14, 2023
Results delay requested
Oct 22, 2024
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04442295
Lead sponsor
Stoke Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 22, 2020
Start date
Jun 29, 2020
Primary completion
Nov 14, 2023
Completion
Nov 14, 2023
Last update
May 18, 2025

Study contacts

Ann Dandurand, MD
study director · Medical Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zorevunersen

Start the discussion